Fatal Outcomes for Two Confirmed Ebola Cases in DRC as Africa Strives to Reboot Immunization Strategies for COVID and Beyond 29/04/2022 Paul Adepoju In DR Congo’s latest Ebola outbreak, the two people with confirmed cases are dead and response is focusing on identifying and vaccinating contacts – because of insufficient doses to conduct a mass vaccination campaign in the outbreak area. Meanwhile, public health officials are trying to reboot Africa’s mainstream immunization programmes, which saw setbacks during the […] Continue reading -> Smart Cervical Cancer Screening Devices Could Make Early Detection a Global Reality 28/04/2022 Maayan Hoffman Qalansawe, Israel – The women, heads covered in hijabs, sat outside a small purple aluminium mobile health station parked in a residential neighbourhood here, shooing away any men who happened to pass by. Plastic chairs formed a small and intimate circle for the women waiting to be screened for cervical cancer – some for the […] Continue reading -> WHO Warns of Dangers of Health Misinformation Across Social Media Following Elon Musk’s $44 bn Twitter Acquisition 27/04/2022 Raisa Santos Following the purchase of Twitter by billionaire Elon Musk on Monday, the World Health Organization warned about the dangers of health and vaccine misinformation on social media, and expressed hope that the acquisition would lead to an ‘improvement of quality information’. “There is misinformation and disinformation out there across whatever platform you wish to go […] Continue reading -> WHO Supports DRC with Ebola Outbreak and Continues Investigation of Unexplained Acute Hepatitis Cases in US and Europe 27/04/2022 Raisa Santos The World Health Organization has announced an outbreak of Ebola in the Democratic Republic of Congo and its continued investigation of almost 200 cases of unexplained acute hepatitis in the US and Europe in a media briefing Tuesday afternoon. Two cases of Ebola have been confirmed in the northwestern Democratic Republic of Congo, prompting health […] Continue reading -> J&J Teams up with African Centre to Find New Drugs to Address Antimicrobial Resistance 25/04/2022 Kerry Cullinan CAPE TOWN – A new partnership between African scientists and pharmaceutical company Johnson & Johnson (J&J), aimed at finding solutions to antimicrobial resistance (AMR), was launched in South Africa on Monday. The J&J Satellite Center for Global Health Discovery, housed at the University of Cape Town (UCT)’s Holistic Drug Discovery and Development (H3D) Center, will […] Continue reading -> Data-Sharing in the Time of COVID – Could Researchers Agree to Use a Common Clinical Trial ‘Repository’? 15/04/2022 Elaine Ruth Fletcher Nathalie Strub-Wourgaft, a senior scientist at the Drugs for Neglected Disease Initiative (DNDi) has a vision that could be critical to halting the next pandemic – but is esoteric, difficult to organize and even more challenging to build the trust and buy-in needed to make it really work. The vision is of a common clinical-trial […] Continue reading -> Global Health Matters: Around the World of Public Health in Audio 13/04/2022 Maayan Hoffman After Dr Garry Aslanyan became an avid follower of podcasts, he realized there was a dearth of material from the genre in his own global health field. So he set out to fill that gap with a new series featuring public health professionals and policymakers from around the world who have made a difference – […] Continue reading -> Championing Health Equity in South Africa – Global Health Matters Podcast Series 13/04/2022 Editorial team The second season of the Global Health Matters podcast series kicks off with a close-up look at South Africa’s health equity initiatives and champions. Health Policy Watch will be featuring episodes from the series throughout the coming year as part of a TDR-supported series. As the world commits to equitable access to medicines and vaccines, […] Continue reading -> Pfizer Refuses Cooperation with DNDi on Study of Paxlovid Treatment Adapted to Low Income Countries 08/04/2022 Elaine Ruth Fletcher & Kerry Cullinan Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading -> Artificial Intelligence ‘Boot Camp’ Aims to Accelerate Drug Discovery 08/04/2022 Maayan Hoffman TEL AVIV – Ninety percent of drug candidates fail in clinical trials because of unexpected safety issues or lack of efficacy in human subjects, according to Noga Yerushalmi, Investment Director at M Ventures, the strategic, corporate venture capital arm of Merck. There have been dramatic improvements in omics technologies – that is the collective technologies […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Smart Cervical Cancer Screening Devices Could Make Early Detection a Global Reality 28/04/2022 Maayan Hoffman Qalansawe, Israel – The women, heads covered in hijabs, sat outside a small purple aluminium mobile health station parked in a residential neighbourhood here, shooing away any men who happened to pass by. Plastic chairs formed a small and intimate circle for the women waiting to be screened for cervical cancer – some for the […] Continue reading -> WHO Warns of Dangers of Health Misinformation Across Social Media Following Elon Musk’s $44 bn Twitter Acquisition 27/04/2022 Raisa Santos Following the purchase of Twitter by billionaire Elon Musk on Monday, the World Health Organization warned about the dangers of health and vaccine misinformation on social media, and expressed hope that the acquisition would lead to an ‘improvement of quality information’. “There is misinformation and disinformation out there across whatever platform you wish to go […] Continue reading -> WHO Supports DRC with Ebola Outbreak and Continues Investigation of Unexplained Acute Hepatitis Cases in US and Europe 27/04/2022 Raisa Santos The World Health Organization has announced an outbreak of Ebola in the Democratic Republic of Congo and its continued investigation of almost 200 cases of unexplained acute hepatitis in the US and Europe in a media briefing Tuesday afternoon. Two cases of Ebola have been confirmed in the northwestern Democratic Republic of Congo, prompting health […] Continue reading -> J&J Teams up with African Centre to Find New Drugs to Address Antimicrobial Resistance 25/04/2022 Kerry Cullinan CAPE TOWN – A new partnership between African scientists and pharmaceutical company Johnson & Johnson (J&J), aimed at finding solutions to antimicrobial resistance (AMR), was launched in South Africa on Monday. The J&J Satellite Center for Global Health Discovery, housed at the University of Cape Town (UCT)’s Holistic Drug Discovery and Development (H3D) Center, will […] Continue reading -> Data-Sharing in the Time of COVID – Could Researchers Agree to Use a Common Clinical Trial ‘Repository’? 15/04/2022 Elaine Ruth Fletcher Nathalie Strub-Wourgaft, a senior scientist at the Drugs for Neglected Disease Initiative (DNDi) has a vision that could be critical to halting the next pandemic – but is esoteric, difficult to organize and even more challenging to build the trust and buy-in needed to make it really work. The vision is of a common clinical-trial […] Continue reading -> Global Health Matters: Around the World of Public Health in Audio 13/04/2022 Maayan Hoffman After Dr Garry Aslanyan became an avid follower of podcasts, he realized there was a dearth of material from the genre in his own global health field. So he set out to fill that gap with a new series featuring public health professionals and policymakers from around the world who have made a difference – […] Continue reading -> Championing Health Equity in South Africa – Global Health Matters Podcast Series 13/04/2022 Editorial team The second season of the Global Health Matters podcast series kicks off with a close-up look at South Africa’s health equity initiatives and champions. Health Policy Watch will be featuring episodes from the series throughout the coming year as part of a TDR-supported series. As the world commits to equitable access to medicines and vaccines, […] Continue reading -> Pfizer Refuses Cooperation with DNDi on Study of Paxlovid Treatment Adapted to Low Income Countries 08/04/2022 Elaine Ruth Fletcher & Kerry Cullinan Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading -> Artificial Intelligence ‘Boot Camp’ Aims to Accelerate Drug Discovery 08/04/2022 Maayan Hoffman TEL AVIV – Ninety percent of drug candidates fail in clinical trials because of unexpected safety issues or lack of efficacy in human subjects, according to Noga Yerushalmi, Investment Director at M Ventures, the strategic, corporate venture capital arm of Merck. There have been dramatic improvements in omics technologies – that is the collective technologies […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
WHO Warns of Dangers of Health Misinformation Across Social Media Following Elon Musk’s $44 bn Twitter Acquisition 27/04/2022 Raisa Santos Following the purchase of Twitter by billionaire Elon Musk on Monday, the World Health Organization warned about the dangers of health and vaccine misinformation on social media, and expressed hope that the acquisition would lead to an ‘improvement of quality information’. “There is misinformation and disinformation out there across whatever platform you wish to go […] Continue reading -> WHO Supports DRC with Ebola Outbreak and Continues Investigation of Unexplained Acute Hepatitis Cases in US and Europe 27/04/2022 Raisa Santos The World Health Organization has announced an outbreak of Ebola in the Democratic Republic of Congo and its continued investigation of almost 200 cases of unexplained acute hepatitis in the US and Europe in a media briefing Tuesday afternoon. Two cases of Ebola have been confirmed in the northwestern Democratic Republic of Congo, prompting health […] Continue reading -> J&J Teams up with African Centre to Find New Drugs to Address Antimicrobial Resistance 25/04/2022 Kerry Cullinan CAPE TOWN – A new partnership between African scientists and pharmaceutical company Johnson & Johnson (J&J), aimed at finding solutions to antimicrobial resistance (AMR), was launched in South Africa on Monday. The J&J Satellite Center for Global Health Discovery, housed at the University of Cape Town (UCT)’s Holistic Drug Discovery and Development (H3D) Center, will […] Continue reading -> Data-Sharing in the Time of COVID – Could Researchers Agree to Use a Common Clinical Trial ‘Repository’? 15/04/2022 Elaine Ruth Fletcher Nathalie Strub-Wourgaft, a senior scientist at the Drugs for Neglected Disease Initiative (DNDi) has a vision that could be critical to halting the next pandemic – but is esoteric, difficult to organize and even more challenging to build the trust and buy-in needed to make it really work. The vision is of a common clinical-trial […] Continue reading -> Global Health Matters: Around the World of Public Health in Audio 13/04/2022 Maayan Hoffman After Dr Garry Aslanyan became an avid follower of podcasts, he realized there was a dearth of material from the genre in his own global health field. So he set out to fill that gap with a new series featuring public health professionals and policymakers from around the world who have made a difference – […] Continue reading -> Championing Health Equity in South Africa – Global Health Matters Podcast Series 13/04/2022 Editorial team The second season of the Global Health Matters podcast series kicks off with a close-up look at South Africa’s health equity initiatives and champions. Health Policy Watch will be featuring episodes from the series throughout the coming year as part of a TDR-supported series. As the world commits to equitable access to medicines and vaccines, […] Continue reading -> Pfizer Refuses Cooperation with DNDi on Study of Paxlovid Treatment Adapted to Low Income Countries 08/04/2022 Elaine Ruth Fletcher & Kerry Cullinan Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading -> Artificial Intelligence ‘Boot Camp’ Aims to Accelerate Drug Discovery 08/04/2022 Maayan Hoffman TEL AVIV – Ninety percent of drug candidates fail in clinical trials because of unexpected safety issues or lack of efficacy in human subjects, according to Noga Yerushalmi, Investment Director at M Ventures, the strategic, corporate venture capital arm of Merck. There have been dramatic improvements in omics technologies – that is the collective technologies […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
WHO Supports DRC with Ebola Outbreak and Continues Investigation of Unexplained Acute Hepatitis Cases in US and Europe 27/04/2022 Raisa Santos The World Health Organization has announced an outbreak of Ebola in the Democratic Republic of Congo and its continued investigation of almost 200 cases of unexplained acute hepatitis in the US and Europe in a media briefing Tuesday afternoon. Two cases of Ebola have been confirmed in the northwestern Democratic Republic of Congo, prompting health […] Continue reading -> J&J Teams up with African Centre to Find New Drugs to Address Antimicrobial Resistance 25/04/2022 Kerry Cullinan CAPE TOWN – A new partnership between African scientists and pharmaceutical company Johnson & Johnson (J&J), aimed at finding solutions to antimicrobial resistance (AMR), was launched in South Africa on Monday. The J&J Satellite Center for Global Health Discovery, housed at the University of Cape Town (UCT)’s Holistic Drug Discovery and Development (H3D) Center, will […] Continue reading -> Data-Sharing in the Time of COVID – Could Researchers Agree to Use a Common Clinical Trial ‘Repository’? 15/04/2022 Elaine Ruth Fletcher Nathalie Strub-Wourgaft, a senior scientist at the Drugs for Neglected Disease Initiative (DNDi) has a vision that could be critical to halting the next pandemic – but is esoteric, difficult to organize and even more challenging to build the trust and buy-in needed to make it really work. The vision is of a common clinical-trial […] Continue reading -> Global Health Matters: Around the World of Public Health in Audio 13/04/2022 Maayan Hoffman After Dr Garry Aslanyan became an avid follower of podcasts, he realized there was a dearth of material from the genre in his own global health field. So he set out to fill that gap with a new series featuring public health professionals and policymakers from around the world who have made a difference – […] Continue reading -> Championing Health Equity in South Africa – Global Health Matters Podcast Series 13/04/2022 Editorial team The second season of the Global Health Matters podcast series kicks off with a close-up look at South Africa’s health equity initiatives and champions. Health Policy Watch will be featuring episodes from the series throughout the coming year as part of a TDR-supported series. As the world commits to equitable access to medicines and vaccines, […] Continue reading -> Pfizer Refuses Cooperation with DNDi on Study of Paxlovid Treatment Adapted to Low Income Countries 08/04/2022 Elaine Ruth Fletcher & Kerry Cullinan Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading -> Artificial Intelligence ‘Boot Camp’ Aims to Accelerate Drug Discovery 08/04/2022 Maayan Hoffman TEL AVIV – Ninety percent of drug candidates fail in clinical trials because of unexpected safety issues or lack of efficacy in human subjects, according to Noga Yerushalmi, Investment Director at M Ventures, the strategic, corporate venture capital arm of Merck. There have been dramatic improvements in omics technologies – that is the collective technologies […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
J&J Teams up with African Centre to Find New Drugs to Address Antimicrobial Resistance 25/04/2022 Kerry Cullinan CAPE TOWN – A new partnership between African scientists and pharmaceutical company Johnson & Johnson (J&J), aimed at finding solutions to antimicrobial resistance (AMR), was launched in South Africa on Monday. The J&J Satellite Center for Global Health Discovery, housed at the University of Cape Town (UCT)’s Holistic Drug Discovery and Development (H3D) Center, will […] Continue reading -> Data-Sharing in the Time of COVID – Could Researchers Agree to Use a Common Clinical Trial ‘Repository’? 15/04/2022 Elaine Ruth Fletcher Nathalie Strub-Wourgaft, a senior scientist at the Drugs for Neglected Disease Initiative (DNDi) has a vision that could be critical to halting the next pandemic – but is esoteric, difficult to organize and even more challenging to build the trust and buy-in needed to make it really work. The vision is of a common clinical-trial […] Continue reading -> Global Health Matters: Around the World of Public Health in Audio 13/04/2022 Maayan Hoffman After Dr Garry Aslanyan became an avid follower of podcasts, he realized there was a dearth of material from the genre in his own global health field. So he set out to fill that gap with a new series featuring public health professionals and policymakers from around the world who have made a difference – […] Continue reading -> Championing Health Equity in South Africa – Global Health Matters Podcast Series 13/04/2022 Editorial team The second season of the Global Health Matters podcast series kicks off with a close-up look at South Africa’s health equity initiatives and champions. Health Policy Watch will be featuring episodes from the series throughout the coming year as part of a TDR-supported series. As the world commits to equitable access to medicines and vaccines, […] Continue reading -> Pfizer Refuses Cooperation with DNDi on Study of Paxlovid Treatment Adapted to Low Income Countries 08/04/2022 Elaine Ruth Fletcher & Kerry Cullinan Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading -> Artificial Intelligence ‘Boot Camp’ Aims to Accelerate Drug Discovery 08/04/2022 Maayan Hoffman TEL AVIV – Ninety percent of drug candidates fail in clinical trials because of unexpected safety issues or lack of efficacy in human subjects, according to Noga Yerushalmi, Investment Director at M Ventures, the strategic, corporate venture capital arm of Merck. There have been dramatic improvements in omics technologies – that is the collective technologies […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Data-Sharing in the Time of COVID – Could Researchers Agree to Use a Common Clinical Trial ‘Repository’? 15/04/2022 Elaine Ruth Fletcher Nathalie Strub-Wourgaft, a senior scientist at the Drugs for Neglected Disease Initiative (DNDi) has a vision that could be critical to halting the next pandemic – but is esoteric, difficult to organize and even more challenging to build the trust and buy-in needed to make it really work. The vision is of a common clinical-trial […] Continue reading -> Global Health Matters: Around the World of Public Health in Audio 13/04/2022 Maayan Hoffman After Dr Garry Aslanyan became an avid follower of podcasts, he realized there was a dearth of material from the genre in his own global health field. So he set out to fill that gap with a new series featuring public health professionals and policymakers from around the world who have made a difference – […] Continue reading -> Championing Health Equity in South Africa – Global Health Matters Podcast Series 13/04/2022 Editorial team The second season of the Global Health Matters podcast series kicks off with a close-up look at South Africa’s health equity initiatives and champions. Health Policy Watch will be featuring episodes from the series throughout the coming year as part of a TDR-supported series. As the world commits to equitable access to medicines and vaccines, […] Continue reading -> Pfizer Refuses Cooperation with DNDi on Study of Paxlovid Treatment Adapted to Low Income Countries 08/04/2022 Elaine Ruth Fletcher & Kerry Cullinan Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading -> Artificial Intelligence ‘Boot Camp’ Aims to Accelerate Drug Discovery 08/04/2022 Maayan Hoffman TEL AVIV – Ninety percent of drug candidates fail in clinical trials because of unexpected safety issues or lack of efficacy in human subjects, according to Noga Yerushalmi, Investment Director at M Ventures, the strategic, corporate venture capital arm of Merck. There have been dramatic improvements in omics technologies – that is the collective technologies […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Global Health Matters: Around the World of Public Health in Audio 13/04/2022 Maayan Hoffman After Dr Garry Aslanyan became an avid follower of podcasts, he realized there was a dearth of material from the genre in his own global health field. So he set out to fill that gap with a new series featuring public health professionals and policymakers from around the world who have made a difference – […] Continue reading -> Championing Health Equity in South Africa – Global Health Matters Podcast Series 13/04/2022 Editorial team The second season of the Global Health Matters podcast series kicks off with a close-up look at South Africa’s health equity initiatives and champions. Health Policy Watch will be featuring episodes from the series throughout the coming year as part of a TDR-supported series. As the world commits to equitable access to medicines and vaccines, […] Continue reading -> Pfizer Refuses Cooperation with DNDi on Study of Paxlovid Treatment Adapted to Low Income Countries 08/04/2022 Elaine Ruth Fletcher & Kerry Cullinan Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading -> Artificial Intelligence ‘Boot Camp’ Aims to Accelerate Drug Discovery 08/04/2022 Maayan Hoffman TEL AVIV – Ninety percent of drug candidates fail in clinical trials because of unexpected safety issues or lack of efficacy in human subjects, according to Noga Yerushalmi, Investment Director at M Ventures, the strategic, corporate venture capital arm of Merck. There have been dramatic improvements in omics technologies – that is the collective technologies […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Championing Health Equity in South Africa – Global Health Matters Podcast Series 13/04/2022 Editorial team The second season of the Global Health Matters podcast series kicks off with a close-up look at South Africa’s health equity initiatives and champions. Health Policy Watch will be featuring episodes from the series throughout the coming year as part of a TDR-supported series. As the world commits to equitable access to medicines and vaccines, […] Continue reading -> Pfizer Refuses Cooperation with DNDi on Study of Paxlovid Treatment Adapted to Low Income Countries 08/04/2022 Elaine Ruth Fletcher & Kerry Cullinan Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading -> Artificial Intelligence ‘Boot Camp’ Aims to Accelerate Drug Discovery 08/04/2022 Maayan Hoffman TEL AVIV – Ninety percent of drug candidates fail in clinical trials because of unexpected safety issues or lack of efficacy in human subjects, according to Noga Yerushalmi, Investment Director at M Ventures, the strategic, corporate venture capital arm of Merck. There have been dramatic improvements in omics technologies – that is the collective technologies […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Pfizer Refuses Cooperation with DNDi on Study of Paxlovid Treatment Adapted to Low Income Countries 08/04/2022 Elaine Ruth Fletcher & Kerry Cullinan Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading -> Artificial Intelligence ‘Boot Camp’ Aims to Accelerate Drug Discovery 08/04/2022 Maayan Hoffman TEL AVIV – Ninety percent of drug candidates fail in clinical trials because of unexpected safety issues or lack of efficacy in human subjects, according to Noga Yerushalmi, Investment Director at M Ventures, the strategic, corporate venture capital arm of Merck. There have been dramatic improvements in omics technologies – that is the collective technologies […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Artificial Intelligence ‘Boot Camp’ Aims to Accelerate Drug Discovery 08/04/2022 Maayan Hoffman TEL AVIV – Ninety percent of drug candidates fail in clinical trials because of unexpected safety issues or lack of efficacy in human subjects, according to Noga Yerushalmi, Investment Director at M Ventures, the strategic, corporate venture capital arm of Merck. There have been dramatic improvements in omics technologies – that is the collective technologies […] Continue reading -> Posts navigation Older postsNewer posts